UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 298

Sortiert nach

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

Clinical cancer research, 2010-02, Vol.16 (4), p.1216-1225

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3958-3964

2007

Link zum Volltext

Verfügbarkeit prüfen

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The lancet oncology, 2020-01, Vol.21 (1), p.95-104

2020

Link zum Volltext

Verfügbarkeit prüfen

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

European urology, 2020-12, Vol.78 (6), p.783-785

2020

Link zum Volltext

Verfügbarkeit prüfen

Temsirolimus in the treatment of advanced renal cell carcinoma

Oncology reviews, 2011-12, Vol.1 (2), p.73-80

Escudier, Bernard J.

2011

Link zum Volltext

Verfügbarkeit prüfen

Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study

Clinical genitourinary cancer, 2021-10, Vol.19 (5), p.468.e1-468.e5

2021

Link zum Volltext

Verfügbarkeit prüfen

Cessation of Vascular Endothelial Growth Factor―Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: Feasibility and Clinical Outcome

Cancer, 2012-07, Vol.118 (13), p.3277-3282

2012

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy in patients with metastatic renal cell carcinoma

Clinical advances in hematology & oncology, 2010-10, Vol.8 (10), p.665

Escudier, Bernard J

2010

Link zum Volltext

Verfügbarkeit prüfen

Temsirolimus in the treatment of advanced renal cell carcinoma

Oncology reviews, 2011-12, Vol.1 (2), p.73-80

Escudier, Bernard J.

2011

Link zum Volltext

Verfügbarkeit prüfen

Renal cell carcinoma: the fastest evolving tumor

Oncology (Williston Park, N.Y.), 2008-04, Vol.22 (4), p.396

Escudier, Bernard J

2008

Link zum Volltext

Verfügbarkeit prüfen

Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference

Cancer, 2009-05, Vol.115 (S10), p.2247-2251

2009

Link zum Volltext

Verfügbarkeit prüfen

Effect of nivolumab on tumor growth rate (TGR) in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.481-481

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4561-4561

2016

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.447-447

2017

Link zum Volltext

Verfügbarkeit prüfen

Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): Retrospective experience at Gustave Roussy

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.527-527

2016

Link zum Volltext

Verfügbarkeit prüfen

A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e16113-e16113

2016

Link zum Volltext

Verfügbarkeit prüfen

Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4569-4569

2017

Link zum Volltext

Verfügbarkeit prüfen

Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS4600-TPS4600

2017

Link zum Volltext

Verfügbarkeit prüfen

Medical therapy for renal cell cancer with pancreatic metastases: Experience of the Gustave Roussy Institute

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.503-503

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.462-462

2017

Link zum Volltext

Verfügbarkeit prüfen

Early replacement of CT scanning by abdomino-pelvic ultrasound as a safe alternative in the follow-up of patients with germ cell tumors

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.420-420

2017

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases (BM) from renal cell carcinoma treated with nivolumab: Evidence of early brain flare?

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.520-520

2017

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2565-2565

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4570-4570

2017

Link zum Volltext

Verfügbarkeit prüfen

Thermal ablation for the treatment of bone metastases (BM) in patients (pts) with metastatic renal cell carcinoma (mRCC): Experience from IGR

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.437-437

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 298

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(289)
Mit Volltextzugriff
(273)

Publikationsform

Artikel
(276)
Reviews
(18)
Bücher
(2)
Buchkapitel
(1)
Texte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(122)
Science & Technology
(122)
Humans
(102)
Oncology
(81)
Female
(61)
Carcinoma, Renal Cell - Drug Therapy
(60)
Male
(60)
Kidney Neoplasms - Drug Therapy
(58)
Middle Aged
(52)
Aged
(47)
Renal Cell Carcinoma
(44)
Biological And Medical Sciences
(40)
Medical Sciences
(40)
Adult
(39)
Kidney Neoplasms - Pathology
(36)
Kidney Cancer
(34)
Immunotherapy
(33)
Disease-Free Survival
(27)
Urology & Nephrology
(27)
Carcinoma, Renal Cell - Pathology
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Temsirolimus in the treatment of advanced renal cell carcinoma

Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study

Cessation of Vascular Endothelial Growth Factor―Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: Feasibility and Clinical Outcome

Combination therapy in patients with metastatic renal cell carcinoma

Temsirolimus in the treatment of advanced renal cell carcinoma

Renal cell carcinoma: the fastest evolving tumor

Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference

Effect of nivolumab on tumor growth rate (TGR) in metastatic renal cell carcinoma (mRCC)

Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR)

Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study

Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): Retrospective experience at Gustave Roussy

A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC)

Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC)

Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)

Medical therapy for renal cell cancer with pancreatic metastases: Experience of the Gustave Roussy Institute

Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Early replacement of CT scanning by abdomino-pelvic ultrasound as a safe alternative in the follow-up of patients with germ cell tumors

Brain metastases (BM) from renal cell carcinoma treated with nivolumab: Evidence of early brain flare?

Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study

Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)

Thermal ablation for the treatment of bone metastases (BM) in patients (pts) with metastatic renal cell carcinoma (mRCC): Experience from IGR

Suchergebnisse filtern